298 related articles for article (PubMed ID: 16187970)
1. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
3. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
7. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
11. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
López Aspiroz E; Santos Buelga D; Cabrera Figueroa S; López Galera RM; Ribera Pascuet E; Domínguez-Gil Hurlé A; García Sánchez MJ
Ther Drug Monit; 2011 Oct; 33(5):573-82. PubMed ID: 21912331
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.
Dailly E; Allavena C; Raffi F; Jolliet P
Br J Clin Pharmacol; 2005 Jul; 60(1):32-4. PubMed ID: 15963091
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
[TBL] [Abstract][Full Text] [Related]
15. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
[TBL] [Abstract][Full Text] [Related]
18. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]